bpc-157 tb-500 promote angiogenesis vs TB-500: Recovery Peptide Comparison BPC-157 + TB-500 Chicago: Wolverine
Description
Farag A
Participants were excluded from the trial if any of the following criteria applied: Glycemia-related HbA 1c 48 mmol mol 1 (6.5%) as measured by the central laboratory at screening
BPC 157 therapy has been performed per-orally, using an effective regimen that restored the myotendinous junction [13]
**Anemia:** Management of certain types of anemia, particularly those related to vitamin B12 or folate deficiency
Lower Risk of Growth-Related Side Effects: Because it does not appear to raise IGF-1 significantly, the peptide may carry fewer systemic risks than traditional growth hormone therapies
